FDA rejection of Dapagliflozin creates uncertainty for other SGLT-2 inhibitors
20 January 2012
Christine Henry
Please Login to read the full article.
20 January 2012
Christine Henry
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA panel rejects BMS/AstraZeneca diabetes drug on cancer, liver injury concerns
- US FDA rejects AZ/BMS diabetes drug dapagliflozin
- BMS and AZ to look at cardiprotective effect if dapagliflozin approved in diabetes
- Cancer a concern for BMS/AstraZeneca drug, but liver injury could be FDA panel focus
FEATURES
Other Informa Features
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
